Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

Elliott Richelson, Terry Souder

Research output: Contribution to journalArticle

526 Citations (Scopus)

Abstract

Using radioligand binding assays and post-mortem normal human brain tissue, we obtained equilibrium dissociation constants (K(d)s) for nine new antipsychotic drugs (iloperidone, melperone, olanzapine, ORG 5222, quetiapine, risperidone, sertindole, ziprasidone, and zotepine), one metabolite of a new drug (9-OH-risperidone), and three older antipsychotics (clozapine, haloperidol, and pimozide) at nine different receptors (α1-adrenergic, α2-adrenergic, dopamine D2, histamine H1, muscarinic, and serotonin 5-HT(1A), 5-HT(1D), 5-HT(2A), and 5-HT(2C) receptors). Iloperidone was the most potent drug at the two adrenergic receptors. ORG 5222 was the most potent drug at dopamine D2 and 5-HT(2c) receptors, while ziprasidone was the most potent compound at three serotonergic receptors (5-HT(1A), 5-HT(1D), and 5-HT(2A)). At the remaining two receptors, olanzapine was the most potent drug at the histamine H1 receptor (K(d)=0.087 nM); clozapine at the muscarinic receptor (K(d)=9 nM). Certain therapeutic and adverse effects, as well as certain drug interactions can be predicted from a drug's potency for blocking a specific receptor. These data can provide guidelines for the clinician in the choice of antipsychotic drug. (C) 2000 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)29-39
Number of pages11
JournalLife Sciences
Volume68
Issue number1
DOIs
StatePublished - Nov 24 2000

Fingerprint

Antipsychotic Agents
Brain
Serotonin
olanzapine
Receptor, Serotonin, 5-HT2C
Pharmaceutical Preparations
Clozapine
Adrenergic Agents
Adrenergic Receptors
Dopamine
Receptor, Serotonin, 5-HT1D
Drug interactions
Pimozide
Histamine H1 Receptors
Radioligand Assay
Dopamine Agents
Risperidone
Muscarinic Receptors
Therapeutic Uses
Haloperidol

Keywords

  • α-Adrenoceptor
  • α-Adrenoceptor
  • Dopamine D receptor
  • Histamine H receptor
  • Muscarinic receptor
  • Serotonin 5-HT(1A) receptor
  • Serotonin 5-HT(2A) receptor

ASJC Scopus subject areas

  • Pharmacology

Cite this

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. / Richelson, Elliott; Souder, Terry.

In: Life Sciences, Vol. 68, No. 1, 24.11.2000, p. 29-39.

Research output: Contribution to journalArticle

Richelson, Elliott ; Souder, Terry. / Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. In: Life Sciences. 2000 ; Vol. 68, No. 1. pp. 29-39.
@article{aa4cc05e157c46e8b2297cdbd7917874,
title = "Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds",
abstract = "Using radioligand binding assays and post-mortem normal human brain tissue, we obtained equilibrium dissociation constants (K(d)s) for nine new antipsychotic drugs (iloperidone, melperone, olanzapine, ORG 5222, quetiapine, risperidone, sertindole, ziprasidone, and zotepine), one metabolite of a new drug (9-OH-risperidone), and three older antipsychotics (clozapine, haloperidol, and pimozide) at nine different receptors (α1-adrenergic, α2-adrenergic, dopamine D2, histamine H1, muscarinic, and serotonin 5-HT(1A), 5-HT(1D), 5-HT(2A), and 5-HT(2C) receptors). Iloperidone was the most potent drug at the two adrenergic receptors. ORG 5222 was the most potent drug at dopamine D2 and 5-HT(2c) receptors, while ziprasidone was the most potent compound at three serotonergic receptors (5-HT(1A), 5-HT(1D), and 5-HT(2A)). At the remaining two receptors, olanzapine was the most potent drug at the histamine H1 receptor (K(d)=0.087 nM); clozapine at the muscarinic receptor (K(d)=9 nM). Certain therapeutic and adverse effects, as well as certain drug interactions can be predicted from a drug's potency for blocking a specific receptor. These data can provide guidelines for the clinician in the choice of antipsychotic drug. (C) 2000 Elsevier Science Inc.",
keywords = "α-Adrenoceptor, α-Adrenoceptor, Dopamine D receptor, Histamine H receptor, Muscarinic receptor, Serotonin 5-HT(1A) receptor, Serotonin 5-HT(2A) receptor",
author = "Elliott Richelson and Terry Souder",
year = "2000",
month = "11",
day = "24",
doi = "10.1016/S0024-3205(00)00911-5",
language = "English (US)",
volume = "68",
pages = "29--39",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

AU - Richelson, Elliott

AU - Souder, Terry

PY - 2000/11/24

Y1 - 2000/11/24

N2 - Using radioligand binding assays and post-mortem normal human brain tissue, we obtained equilibrium dissociation constants (K(d)s) for nine new antipsychotic drugs (iloperidone, melperone, olanzapine, ORG 5222, quetiapine, risperidone, sertindole, ziprasidone, and zotepine), one metabolite of a new drug (9-OH-risperidone), and three older antipsychotics (clozapine, haloperidol, and pimozide) at nine different receptors (α1-adrenergic, α2-adrenergic, dopamine D2, histamine H1, muscarinic, and serotonin 5-HT(1A), 5-HT(1D), 5-HT(2A), and 5-HT(2C) receptors). Iloperidone was the most potent drug at the two adrenergic receptors. ORG 5222 was the most potent drug at dopamine D2 and 5-HT(2c) receptors, while ziprasidone was the most potent compound at three serotonergic receptors (5-HT(1A), 5-HT(1D), and 5-HT(2A)). At the remaining two receptors, olanzapine was the most potent drug at the histamine H1 receptor (K(d)=0.087 nM); clozapine at the muscarinic receptor (K(d)=9 nM). Certain therapeutic and adverse effects, as well as certain drug interactions can be predicted from a drug's potency for blocking a specific receptor. These data can provide guidelines for the clinician in the choice of antipsychotic drug. (C) 2000 Elsevier Science Inc.

AB - Using radioligand binding assays and post-mortem normal human brain tissue, we obtained equilibrium dissociation constants (K(d)s) for nine new antipsychotic drugs (iloperidone, melperone, olanzapine, ORG 5222, quetiapine, risperidone, sertindole, ziprasidone, and zotepine), one metabolite of a new drug (9-OH-risperidone), and three older antipsychotics (clozapine, haloperidol, and pimozide) at nine different receptors (α1-adrenergic, α2-adrenergic, dopamine D2, histamine H1, muscarinic, and serotonin 5-HT(1A), 5-HT(1D), 5-HT(2A), and 5-HT(2C) receptors). Iloperidone was the most potent drug at the two adrenergic receptors. ORG 5222 was the most potent drug at dopamine D2 and 5-HT(2c) receptors, while ziprasidone was the most potent compound at three serotonergic receptors (5-HT(1A), 5-HT(1D), and 5-HT(2A)). At the remaining two receptors, olanzapine was the most potent drug at the histamine H1 receptor (K(d)=0.087 nM); clozapine at the muscarinic receptor (K(d)=9 nM). Certain therapeutic and adverse effects, as well as certain drug interactions can be predicted from a drug's potency for blocking a specific receptor. These data can provide guidelines for the clinician in the choice of antipsychotic drug. (C) 2000 Elsevier Science Inc.

KW - α-Adrenoceptor

KW - α-Adrenoceptor

KW - Dopamine D receptor

KW - Histamine H receptor

KW - Muscarinic receptor

KW - Serotonin 5-HT(1A) receptor

KW - Serotonin 5-HT(2A) receptor

UR - http://www.scopus.com/inward/record.url?scp=0034711425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034711425&partnerID=8YFLogxK

U2 - 10.1016/S0024-3205(00)00911-5

DO - 10.1016/S0024-3205(00)00911-5

M3 - Article

C2 - 11132243

AN - SCOPUS:0034711425

VL - 68

SP - 29

EP - 39

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 1

ER -